Tenaya Therapeutics, Inc.: Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
Heart Failure 2022 Presentation Includes Preclinical Data Supporting TN-301 Effect in HFpEF Models TN-301 IND Submission on Track for Second Half of 2022 Tenaya Therapeutics, Inc. (NASDAQ: TNYA)
Source: finanznachrichten.de